tiprankstipranks
Bright Minds Biosciences (TSE:DRUG)
CNQX:DRUG

Bright Minds Biosciences (DRUG) Stock Price & Analysis

6 Followers

DRUG Stock Chart & Stats

Day’s RangeC$0 - C$0
52-Week RangeC$1.47 - C$8.58
Previous CloseC$1.47
Volume100.00
Average Volume (3M)2.26K
Market Cap
C$7.13M
Enterprise Value-C$324.31K
Total Cash (Recent Filing)C$6.75M
Total Debt (Recent Filing)C$73.55K
Price to Earnings (P/E)-0.8
Beta0.58
May 27, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding4,463,837
10 Day Avg. Volume2,846
30 Day Avg. Volume2,262
Standard Deviation0.27
R-Squared0.05
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.74
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

DRUG FAQ

What was Bright Minds Biosciences’s price range in the past 12 months?
Bright Minds Biosciences lowest stock price was C$1.47 and its highest was C$8.58 in the past 12 months.
    What is Bright Minds Biosciences’s market cap?
    Currently, no data Available
    When is Bright Minds Biosciences’s upcoming earnings report date?
    Bright Minds Biosciences’s upcoming earnings report date is May 27, 2024 which is in 29 days.
      How were Bright Minds Biosciences’s earnings last quarter?
      Bright Minds Biosciences released its earnings results on Feb 12, 2024. The company reported -C$0.438 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.438.
        Is Bright Minds Biosciences overvalued?
        According to Wall Street analysts Bright Minds Biosciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Bright Minds Biosciences pay dividends?
          Bright Minds Biosciences does not currently pay dividends.
          What is Bright Minds Biosciences’s EPS estimate?
          Bright Minds Biosciences’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Bright Minds Biosciences have?
          Bright Minds Biosciences has 4,319,813 shares outstanding.
            What happened to Bright Minds Biosciences’s price movement after its last earnings report?
            Bright Minds Biosciences reported an EPS of -C$0.438 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Bright Minds Biosciences?
              Currently, no hedge funds are holding shares in TSE:DRUG
              ---

              Bright Minds Biosciences Stock Smart Score

              N/A
              Not Ranked
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -65.41%
              12-Months-Change

              Fundamentals

              Return on Equity
              -79.07%
              Trailing 12-Months
              Asset Growth
              -40.37%
              Trailing 12-Months

              Company Description

              Bright Minds Biosciences

              Bright Minds Biosciences Inc is a pre-clinical biosciences company. It is is focused on developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Sunshine Biopharma
              Resverlogix
              Revive Therapeutics
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis